In the News | Friends of Cancer Research

You are here

In the News

November 25, 2019
Tumor mutational burden (TMB) has generated interest as a potential biomarker of response to immunotherapy and has already been examined in the context of several lung cancer trials to gauge its... Read more
November 20, 2019
Washington, DC – November 20, 2019 – Today, Dr. Stephen Hahn, President Trump’s nominee to be the next Commissioner of the U.S. Food and Drug Administration (FDA), appeared before the Senate Health,... Read more
November 12, 2019
New Project Aims to Harmonize ctDNA for Monitoring Treatment Response   Washington, DC – November 12, 2019 – Today, Friends of Cancer Research (Friends) announced the launch of its latest project,... Read more
November 12, 2019
The US Food and Drug Administration (FDA) may expand a pilot project that allows for simultaneous drug approval decisions from US, Canadian and Australian regulators to include Singapore and... Read more
October 30, 2019
The number of expedited FDA approvals for cancer drugs that are based on surrogate end points is increasing, leading many to search for new ways to uncover efficacy and safety data to justify the... Read more
October 30, 2019
Sudip Parikh has helped shape U.S. science policy as a staffer on a powerful congressional spending panel. He’s been a senior health care executive for a large nonprofit organization that manages... Read more
October 25, 2019
On September 24, 2019, Friends of Cancer Research (Friends) hosted its 23rd Annual Cancer Leadership Awards Reception. The event honored individuals who have been champions of cancer research and... Read more
October 24, 2019
A decade before he became the US Surgeon General, Vivek Murthy, MD, published a 2004 study in JAMA about participants in cancer clinical trials. Among other findings, Murthy and his coauthors... Read more
October 24, 2019
Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses clinical trial eligibility criteria in lung cancer.   Kim led a task force that evaluated the impact... Read more
October 22, 2019
Executive Summary US FDA is encouraging common mechanisms of drug testing to enable pharma industry collaboration and avoid redundancy; Pazdur notes that there are many similar PD-1 drugs.   Richard... Read more

Pages